PHCR.F Stock Overview
Provides specialty diagnostic services to consumer and practitioners in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Healius Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.97 |
| 52 Week High | AU$0.97 |
| 52 Week Low | AU$0.97 |
| Beta | 0.70 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -67.12% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| PHCR.F | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | 1.1% |
| 1Y | n/a | 2.2% | 22.5% |
Return vs Industry: Insufficient data to determine how PHCR.F performed against the US Healthcare industry.
Return vs Market: Insufficient data to determine how PHCR.F performed against the US Market.
Price Volatility
| PHCR.F volatility | |
|---|---|
| PHCR.F Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 6.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: PHCR.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PHCR.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 10,500 | Paul Anderson | www.healius.com.au |
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services.
Healius Limited Fundamentals Summary
| PHCR.F fundamental statistics | |
|---|---|
| Market cap | US$695.08m |
| Earnings (TTM) | -US$661.09m |
| Revenue (TTM) | US$1.14b |
0.6x
P/S Ratio-1.1x
P/E RatioIs PHCR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHCR.F income statement (TTM) | |
|---|---|
| Revenue | AU$1.69b |
| Cost of Revenue | AU$1.16b |
| Gross Profit | AU$532.00m |
| Other Expenses | AU$1.52b |
| Earnings | -AU$984.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 21, 2024
| Earnings per share (EPS) | -1.36 |
| Gross Margin | 31.45% |
| Net Profit Margin | -58.17% |
| Debt/Equity Ratio | 39.3% |
How did PHCR.F perform over the long term?
See historical performance and comparison